Looking ahead to Earth Day later this month, CSL's Chief Sustainability Officer Jeffrey Ball shared an update about our environmental sustainability progress so far. Read more: bit.ly/3J00D8R #CSL #Sustainability #EarthDay

Our #WFH2024 symposium will explore ways to optimize the route to diagnosis and treatment in #VWD , on Tuesday 23 April 12:45–13:45 CET. Join us at the IFEMA Convention Centre in Madrid, Spain and register for #WFHCongress here wfh.org/congress/regis…

#LightUpforRare in Marburg, Germany! Check out Marburg's historic Town Hall illuminated to honor rare disease patients on #RareDiseaseDay . More: bit.ly/3IgPRuz

It’s #RareDiseaseDay and CSL has joined the Global Chain of Lights in Bern, Switzerland! All day, teams of green-minded people rode stationary bicycles to generate the energy needed to #LightUpforRare at Burgerspital Bern. bit.ly/48DOZe5

Tomorrow at #AAAAI24 , we’re hosting an interactive symposium from our esteemed faculty on a mysterious disease state. Uncover the secret and solve the patient puzzle, while learning about how to optimize patient care from diagnosis to disease management. #DrivenByOurPromise

Join our live Meet the Experts series at #AAAAI24 for perspectives on primary immunodeficiency. Hear from a patient advocate on their experience with diagnosis and treatment, and experts Dr. Heimall and Dr. Mustafa on managing complex #PID cases. #DrivenByOurPromise

We’re attending the AAAAI Annual Meeting in Washington, DC from February 23-26! Come to our Meet the Experts series on diagnosing and treating #PID at our booth #325 and tune in to our interactive symposium on optimizing the patient experience. #AAAAI24 #DrivenByOurPromise

CEO and Managing Director Paul McKenzie speaks to the outlook for CSL. A recording of our half year earnings webcast can be found at our investor center: bit.ly/48a7qa4

CSL's CEO and Managing Director Paul McKenzie summarizes our financial performance for the first half of FY2024. More: bit.ly/3UAAILJ

We have just released our half year results for financial year 2024. Check out a snapshot below, or head to our investor center for more information. bit.ly/42F1ioX

CSL’s Head of Research & Development, Dr. Bill Mezzanotte, weighs in on how the AEGIS-II program has left a lasting impact on our organization. Read more: bit.ly/3OGKIzg

Today, we announced top-line results from the Phase 3 AEGIS-II trial. Read more: bit.ly/49xxNYs

This week marks Women’s Heart Week, a time to support education, prevention and early intervention around #HeartHealth , not just for women, but for all individuals.

Dr. Duffy reflects on the importance of conversations around women’s heart health and CSL’s commitment to CVD.

Today is American Heart Association’s National #WearRedDay . We’re proud to show our support and continue to educate others on the risks of heart disease. Get involved at: bit.ly/3uaWSts #WearRedAndGive @GoRedforWomen #HeartMonth

February is American #HeartMonth , and CSL is determined to do our part in the fight against #HeartDisease . We strive to pave the way for a better future for CV patients worldwide through our #cardiovascular and metabolic research program.

A beautiful summer morning dawns with the sun shining on CSL’s Global Headquarters and Centre for R&D, which stands proudly as a landmark on the Melbourne skyline, and in the heart of the biomedical district.
📷: walking_perspective/Instagram #CSL #Melbourne #Summer

A beautiful summer morning dawns with the sun shining on CSL’s Global Headquarters and Centre for R&D, which stands proudly as a landmark on the Melbourne skyline, and in the heart of the biomedical district.
📷: walking_perspective/Instagram #CSL #Melbourne #Summer

At CSL, we are committed to developing innovative treatment options for the rare disease community. The acceptance of our BLA and MAA for our first-ever homegrown mAb, garadacimab, reflects our commitment to #HereditaryAngioedema patients.

We are proud to announce the US FDA has accepted our BLA for garadacimab as a potential treatment option for #HereditaryAngioedema (HAE). The EU EMA has also accepted our MAA for garadacimab. Read more on the latest in HAE here: prn.to/48ixVul

In recognition of #Alpha1Awareness Month in the U.S., we are proud to support the Alpha-1 Foundation in raising awareness of this rare disease. Learn how you can get involved: bit.ly/3upAvQp #A1VW23 #DrivenByOurPromise